Clinical Trials Logo

Peritoneal Cancer clinical trials

View clinical trials related to Peritoneal Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02487849 Withdrawn - Clinical trials for Fallopian Tube Cancer

HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma

HIPEC
Start date: August 2016
Phase: Phase 2
Study type: Interventional

The combination of optimal cytoreductive operation (according to Desktop II criteria), HIPEC with Carboplatin 800 mg/m² KOF (Körperoberfläche) and following platinum-based systemic chemotherapy should be executed In patients with platinum-sensitive recurrence of ovarian carcinoma. Condition for HIPEC is attainment of optimal cytoreduction (R0) and experts judgement of a complication-free prolongation of narcosis after finishing the surgery. HIPEC will be administered additionally to standard therapy. If HIPEC was executed the number of systemic given platinum-based chemotherapy decreases for one cycle. This regime should be investigated in terms of safety of performance, quality of life for the patients and consequences for the following systemic chemotherapy.

NCT ID: NCT01661868 Withdrawn - Ovarian Cancer Clinical Trials

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Start date: August 2012
Phase: Phase 2
Study type: Interventional

This research study is a way of gaining new knowledge about a drug called olaparib in women who have either: 1)never received a PARP inhibitor before to treat ovarian cancer (group 1) or 2)participants who have received a PARP inhibitor before to treat ovarian cancer, with the exception of olaparib (group 2). PARP inhibitors are drugs tht prevent cancer cells from repairing their DNA. In this research study, we are looking to see how well the drug olaparib works in women who have never received a PARP inhibitor for recurrent ovarian cancer as well as those who have received a prior PARP inhibitor and whose cancer has re-grown after receiving that PARP inhibitor.

NCT ID: NCT00634894 Withdrawn - Ovarian Cancer Clinical Trials

Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: March 2008
Phase: Phase 2
Study type: Interventional

Primary Objective: 1. Evaluate the efficacy of letrozole to increase the duration of progression-free survival (defined as time to earliest occurrence of local or distant recurrence or clinically significant elevation in CA-125) when used as adjuvant treatment after completion of primary surgery and first line platinum containing chemotherapy in patients with optimally debulked (< 1 cm residual disease) stage IIA-IIIC ovarian, fallopian tube, or primary peritoneal cancer. Secondary Objective: 1. Observe the incidence of local and distant recurrences.